| Date | Title | | | 12/15/15 | ACADIA Pharmaceuticals Appoints Julian C. Baker to Board of Directors| SAN DIEGO--(BUSINESS WIRE)--Dec. 15, 2015--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
to address unmet medical needs in central nervous system disorders,
today announced Julian C. Baker has joined its Board of Directors.
“After more than 20 years as a professional investor, Julian has
extensive experience in financing and building companies in t... |
|  | | 11/30/15 | ACADIA Pharmaceuticals Appoints Srdjan (Serge) Stankovic, M.D., M.S.P.H., as Executive Vice President, Head of Research and Development| SAN DIEGO--(BUSINESS WIRE)--Nov. 30, 2015--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
to address unmet medical needs in central nervous system (CNS)
disorders, today announced the appointment of Srdjan (Serge) Stankovic,
M.D., M.S.P.H., as Executive Vice President, Head of Research and
Development. With a background in clinical and academic psychiatry, ... |
| | | 11/30/15 | ACADIA Pharmaceuticals Appoints Edmund P. Harrigan, M.D., to Board of Directors| SAN DIEGO--(BUSINESS WIRE)--Nov. 30, 2015--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
to address unmet medical needs in central nervous system (CNS)
disorders, today announced Edmund P. Harrigan, M.D., has joined its
Board of Directors. Dr. Harrigan is a board-certified neurologist with
25 years of executive leadership experience in the pharmaceutical
... |
| | | 11/05/15 | ACADIA Pharmaceuticals Reports Third Quarter 2015 Financial Results| SAN DIEGO--(BUSINESS WIRE)--Nov. 5, 2015--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
to address unmet medical needs in central nervous system disorders,
today announced its unaudited financial results for the third quarter
ended September 30, 2015.
ACADIA reported a net loss of $38.9 million, or $0.39 per common share,
for the third quart... |
| | | 11/04/15 | ACADIA Pharmaceuticals to Present at the 24th Annual Credit Suisse Healthcare Conference on November 10, 2015| SAN DIEGO--(BUSINESS WIRE)--Nov. 4, 2015--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
to address unmet medical needs in central nervous system disorders,
today announced that it will present at the 24th Annual
Credit Suisse Healthcare Conference on Tuesday, November 10, 2015, at
11:30 a.m. Mountain Standard Time in Scottsdale, Arizona.
A l... |
| | | 11/02/15 | ACADIA Pharmaceuticals Announces FDA Priority Review of NUPLAZID™ (Pimavanserin) New Drug Application for Parkinson’s Disease Psychosis| PDUFA Date Set for May 1, 2016
SAN DIEGO--(BUSINESS WIRE)--Nov. 2, 2015--
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
to address unmet medical needs in central nervous system disorders,
today announced that the New Drug Application (NDA) for NUPLAZID™ (pimavanserin)
has been accepted for review by the U.S. Food and Drug Administration
(FDA) and ... |
| | | 10/29/15 | ACADIA Pharmaceuticals to Announce Third Quarter Financial Results on November 5, 2015| ACADIA to Host Conference Call and Webcast on Thursday, November 5,
2015, at 5:00 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--Oct. 29, 2015--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
that address unmet medical needs in central nervous system disorders,
today announced that it will report its unaudited financial results for
the thir... |
| | | 09/22/15 | ACADIA Pharmaceuticals to Present at the Ladenburg Thalmann 2015 Healthcare Conference on September 29, 2015| SAN DIEGO--(BUSINESS WIRE)--Sep. 22, 2015--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
to address unmet medical needs in central nervous system disorders,
today announced that it will present at the Ladenburg Thalmann 2015
Healthcare Conference on Tuesday, September 29, 2015, at 10:00 a.m.
Eastern Time in New York City.
A live webcast of A... |
| | | 09/03/15 | ACADIA Pharmaceuticals Appoints Steve Davis as Chief Executive Officer| SAN DIEGO--(BUSINESS WIRE)--Sep. 3, 2015--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
to address unmet medical needs in central nervous system disorders,
today announced that its Board of Directors has appointed Steve Davis as
President and Chief Executive Officer. Mr. Davis has been serving as
ACADIA’s Interim Chief Executive Officer since March 2015. M... |
| | | 09/03/15 | ACADIA Pharmaceuticals Submits New Drug Application for NUPLAZID™ for the Treatment of Parkinson’s Disease Psychosis| SAN DIEGO--(BUSINESS WIRE)--Sep. 3, 2015--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
to address unmet medical needs in central nervous system disorders,
today announced it has submitted a New Drug Application (NDA) to the
U.S. Food and Drug Administration (FDA) seeking approval for NUPLAZID™
(pimavanserin) for the treatment of psychosis associated with
... |
| | | 08/06/15 | ACADIA Pharmaceuticals Reports Second Quarter 2015 Financial Results| SAN DIEGO--(BUSINESS WIRE)--Aug. 6, 2015--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
that address unmet medical needs in neurological and related central
nervous system disorders, today announced its unaudited financial
results for the second quarter ended June 30, 2015.
ACADIA reported a net loss of $39.4 million, or $0.39 per common share,
... |
| | | 08/06/15 | ACADIA Pharmaceuticals Announces Publication of Data from Its -015 Open Label Safety Study in Parkinson’s Disease Psychosis in the Journal of the American Medical Directors Association| SAN DIEGO--(BUSINESS WIRE)--Aug. 6, 2015--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
that address unmet medical needs in neurological and related central
nervous system disorders, today announced the publication of new data
from its ongoing open-label safety extension study, the -015 Study, with
NUPLAZID™ in patients with Parkinson’s disease psychosis (... |
| | | 08/05/15 | ACADIA Pharmaceuticals Announces Senior Management Appointments in Manufacturing, Quality, Compliance, Access and Reimbursement and Business Development| SAN DIEGO--(BUSINESS WIRE)--Aug. 5, 2015--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
that address unmet medical needs in neurological and related central
nervous system disorders, today announced the following senior
management appointments:
James A. Nash, Senior Vice President, Technology Development and
Operations
... |
| | | 07/30/15 | ACADIA Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2015| ACADIA to Host Conference Call and Webcast on Thursday, August 6,
2015, at 5:00 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--Jul. 30, 2015--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
that address unmet medical needs in neurological and related central
nervous system disorders, today announced that it will report its
unaudited financi... |
| | | 06/17/15 | ACADIA Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 24, 2015| SAN DIEGO--(BUSINESS WIRE)--Jun. 17, 2015--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurological and related central nervous system disorders, today
announced that it will present at the JMP Securities Life Sciences
Conference on Wednesday, June 24, 2015, at 11:00 a.m. Eastern Time in
New York City.
A live webcast of ACADIA’s presentation w... |
| | | 06/16/15 | ACADIA Pharmaceuticals Presents Integrated Data from Its Phase III Program with NUPLAZID™ (Pimavanserin) for Parkinson’s Disease Psychosis at the 19th International Congress of Parkinson’s Disease and Movement Disorders| Data from Integrated Analysis of Two Phase III Studies Show Robust
and Consistent Efficacy of NUPLAZID Across a Wide Array of Study Measures
Data from Two Open-Label Studies Demonstrate Attractive Safety and
Tolerability Profile and Potential for Long-Term Effectiveness of
NUPLAZID in Parkinson’s Disease Psychosis
SAN DIEGO--(BUSINESS WIRE)--Jun. 16, 2015--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
... |
| | | 05/26/15 | ACADIA Pharmaceuticals to Present at the Jefferies 2015 Healthcare Conference on June 2, 2015| SAN DIEGO--(BUSINESS WIRE)--May 26, 2015--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurological and related central nervous system disorders, today
announced that it will present at the Jefferies 2015 Healthcare
Conference on Tuesday, June 2, 2015, at 1:30 p.m. Eastern Time in New
York City.
A live webcast of ACADIA’s presentation will be a... |
| | | 05/07/15 | ACADIA Pharmaceuticals Reports First Quarter 2015 Financial Results| SAN DIEGO--(BUSINESS WIRE)--May 7, 2015--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
that address unmet medical needs in neurological and related central
nervous system disorders, today announced its unaudited financial
results for the first quarter ended March 31, 2015.
ACADIA reported a net loss of $40.4 million, or $0.40 per common share,
... |
| | | 05/06/15 | ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch 2015 Health Care Conference on May 13, 2015| SAN DIEGO--(BUSINESS WIRE)--May 6, 2015--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurological and related central nervous system disorders, today
announced that it will present at the Bank of America Merrill Lynch 2015
Health Care Conference on Wednesday, May 13, 2015, at 4:20 p.m. Pacific
Time in Las Vegas.
A live webcast of ACADIA’s pres... |
| | | 04/30/15 | ACADIA Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2015| ACADIA to Host Conference Call and Webcast on Thursday, May 7, 2015,
at 5:00 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--Apr. 30, 2015--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
that address unmet medical needs in neurological and related central
nervous system disorders, today announced that it will report its
unaudited financial results ... |
| | | 04/07/15 | ACADIA Pharmaceuticals to Present at the 14th Annual Needham Healthcare Conference on April 14, 2015| SAN DIEGO--(BUSINESS WIRE)--Apr. 7, 2015--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurological and related central nervous system disorders, today
announced that it will present at the 14th Annual Needham
Healthcare Conference on Tuesday, April 14, 2015, at 9:20 a.m. Eastern
Time in New York City.
A live webcast of ACADIA’s presentation wi... |
| | | 03/26/15 | ACADIA Pharmaceuticals Appoints Daniel Soland to Board of Directors| SAN DIEGO--(BUSINESS WIRE)--Mar. 26, 2015--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
that address unmet medical needs in neurological and related central
nervous system disorders, today announced that Daniel Soland has joined
its Board of Directors. Mr. Soland is a seasoned pharmaceutical
executive with over 30 years of experience in the biopharmaceuti... |
| | | 03/11/15 | ACADIA Pharmaceuticals Announces Retirement of Uli Hacksell, Ph.D., Chief Executive Officer| Steve Davis Appointed Interim Chief Executive Officer
SAN DIEGO--(BUSINESS WIRE)--Mar. 11, 2015--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
that address unmet medical needs in neurological and related central
nervous system disorders, today announced that Uli Hacksell, Ph.D., has
retired as ACADIA’s Chief Executive Officer and as a member of the Boa... |
| | | 03/11/15 | ACADIA Pharmaceuticals Updates Planned Timing of NUPLAZID™ NDA Submission| Conference Call Scheduled for Today, March 11, at 5:00 p.m. Eastern
Time
SAN DIEGO--(BUSINESS WIRE)--Mar. 11, 2015--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
that address unmet medical needs in neurological and related central
nervous system disorders, today provided an update on the planned timing
of its NUPLAZIDTM (pimavanserin) New Drug A... |
| | | 02/26/15 | ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2014| SAN DIEGO--(BUSINESS WIRE)--Feb. 26, 2015--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
that address unmet medical needs in neurological and related central
nervous system disorders, today announced its financial results for the
fourth quarter and year ended December 31, 2014.
ACADIA reported a net loss of $28.4 million, or $0.28 per common share,... |
| | | 02/24/15 | ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences| SAN DIEGO--(BUSINESS WIRE)--Feb. 24, 2015--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurological and related central nervous system disorders, today
announced that it will present at the following investor conferences:
The Cowen and Company 35th Annual Health Care Conference on
Tuesday, March 3, 2015, at 10:40 a.m. Eastern Time in Bost... |
| | | 02/19/15 | ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2014 Financial Results on February 26, 2015| ACADIA to Host Conference Call and Webcast on Thursday, February 26,
2015, at 5:00 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--Feb. 19, 2015--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
that address unmet medical needs in neurological and related central
nervous system disorders, today announced that it will report its
financial resu... |
| | | 01/06/15 | ACADIA Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference on January 13, 2015| SAN DIEGO--(BUSINESS WIRE)--Jan. 6, 2015--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurological and related central nervous system disorders, today
announced that it will present at the 33rd Annual J.P. Morgan Healthcare
Conference on Tuesday, January 13, 2015, at 11:30 a.m. Pacific Time in
San Francisco.
A live webcast of ACADIA’s presenta... |
| |
|
